Additive Effect for Calorie Limit, Exercise on Glucoregulation

This article originally appeared here.
Share this content:
Additive Effect for Calorie Limit, Exercise on Glucoregulation
Additive Effect for Calorie Limit, Exercise on Glucoregulation

TUESDAY, April 21, 2015 (HealthDay News) -- Calorie restriction (CR) and exercise (EX)-induced weight loss have additive benefits on glucoregulation, according to a study published online April 15 in Diabetes Care.

Edward P. Weiss, Ph.D., from Saint Louis University, and colleagues examined whether CR has additive benefits to those from EX-induced weight loss. Fifty-two sedentary overweight men and women (45 to 65 years of age) were randomized to undergo 6 to 8 percent weight loss by CR, EX, or CR and EX (CREX). During frequently sampled oral glucose tolerance tests, the authors measured glucose, insulin, C-peptide, insulin sensitivity, and incretin hormones (glucagon-like peptide 1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]).

The researchers found that weight losses were similar in all groups, but insulin sensitivity index values increased two-fold more in the CREX group versus the CR and EX groups. In the CR group only, postprandial GLP-1 concentrations decreased (P = 0.04); in all groups, GIP concentrations decreased. There was no change in incretin effects on insulin secretion.

"These findings underscore the importance of promoting both CR and EX for optimal health," the authors write. "However, because data from participants who withdrew from the study and from those who did not adhere to the intervention were excluded, the results may be limited to individuals who are capable of adhering to a healthy lifestyle intervention."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths